Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on April 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). $150M term loan drawn April 16, 2026, refinancing the prior credit facility and increasing near-term liquidity.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $150M term loan drawn April 16, 2026, refinancing the prior credit facility and increasing near-term liquidity
- Additional $75M delayed-draw capacity available for 24 months, subject to secured leverage ratio not exceeding 1.75:1.00
- Floating-rate debt priced at Term SOFR plus 6.25%, with 3.00% SOFR floor and 1.00% fee on undrawn delayed capacity
- Maturity April 16, 2031, but potential acceleration 91 days before 2028 notes maturity if liquidity conditions are unmet
- ABL revolver reduced from $100M to $50M while maturity extends to April 16, 2031, limiting committed borrowing capacity and refinancing pressure
Item 1.02 · Termination of a Material Definitive Agreement
- Prior Credit Agreement terminated upon entry into the new Term Loan Agreement
- Debt obligations transitioned to replacement financing, with terms detailed in the Term Loan Agreement
- Investors should assess refinancing costs, interest rates, maturities, and covenant changes in the new facility
Item 7.01 · Regulation FD Disclosure
- Emergent announced a Term Loan Agreement and ABL Amendment, signaling changes to its debt financing structure
- Exhibit 99.1 contains the substantive transaction terms and investor-relevant financial details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.